India has recorded 36,604 fresh Covid-19 cases, the lowest in more than three months. The previous low before this was 101 days ago on July 17, when 35,065 fresh cases were recorded.
The daily caseload was low as many states recorded their lowest tally in several months as the spread of infections has shown clear signs of slowing down since September 17, the peak of the pandemic.
The global tally of coronavirus cases stands at 43,769,605. While 32,162,688 have recovered, 1,164,228 have died so far. The US, the worst-hit country, has 8,961,851 cases. It is followed by India, which has 7,945,888 cases, Brazil (5,411,550) and Russia (1,531,224).
The Covid-19 vaccine being developed by the University of Oxford produced an immune response in both elderly and young people and adverse reactions were lower among the elderly, British drug maker AstraZeneca Plc said on Monday. A vaccine that works is seen as a game-changer in the battle against the novel coronavirus.
Amid the race to develop a ‘potential’ vaccine against novel coronavirus pandemic, India’s first indigenously developed Covid-19 vaccine, Covaxin will commence its Phase III clinical trials at a private hospital in Bhubaneswar soon, an official said.
The search for a suitable vaccine for Covid-19 has almost come to the final stage, Dr E Venkata Rao, Principal Investigator in the Covaxin human trial and Professor in the department of Community Medicine at the Institute of Medical Sciences and SUM Hospital said.
The Chairperson of the Scientific Advisory Committee, National Institute of Epidemiology – Dr Jayaprakash Muliyil, has told CNBC-TV18 that the reduction in the number of new cases is quite promising, exciting and real. According to him, the only explanation is that more regions of the country are not showing signs of herd immunity and that there are no other plausible explanations for drop, expect a high level of immunity in the population.